# EDGAR Filing Document

**Accession Number:** 0001368514
**File Stem:** 0000000000-25-007484
**Filing Date:** 2025-7
**Character Count:** 4152
**Document Hash:** 27545fc67d4996d0b97eec30ebec38eb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-007484.hdr.sgml**: 20260225

**ACCESSION NUMBER**: 0000000000-25-007484

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250716

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ADMA BIOLOGICS, INC.
- **CENTRAL INDEX KEY:** 0001368514
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 562590442
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 001-36728

**BUSINESS ADDRESS:**
- **STREET 1:** C/O ADMA BIOLOGICS, INC.
- **STREET 2:** 465 STATE ROUTE 17
- **CITY:** RAMSEY
- **STATE:** NJ
- **ZIP:** 07446
- **BUSINESS PHONE:** (201) 478-5552

**MAIL ADDRESS:**
- **STREET 1:** C/O ADMA BIOLOGICS, INC.
- **STREET 2:** 465 STATE ROUTE 17
- **CITY:** RAMSEY
- **STATE:** NJ
- **ZIP:** 07446

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** R&R ACQUISITION VI, INC
- **DATE OF NAME CHANGE:** 20060707
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001140361-25-009257

## Text-Extract

```

                                                            July 16, 2025

Brad Tade
Chief Financial Officer & Treasurer
ADMA Biologics, Inc.
465 State Route 17
Ramsey, New Jersey 07446

       Re: ADMA Biologics, Inc.
           Form 10-K for the fiscal year ended December 31, 2024
           Filed March 18, 2025
           File No. 001-36728
Dear Brad Tade:

       We have limited our review of your filing to the financial statements
and related
disclosures and have the following comment.

       Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe
the comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to this letter, we may have additional
comments.

Form 10-K for the fiscal year ended December 31, 2024
Management's Discussion and Analysis of Financial Condition and Results of
Operations,
page 68
Results of Operations, page 70

1.     We note your analysis of revenues for the periods presented on pages 73
and 75,
       including the 65% increase in revenue in 2024 and improved operating
results which
       contributed to net income on a GAAP basis for the first time, and your
expectation
       of increased physician, payer and patient acceptance and utilization of
ASCENIV, as
       well as sales increases for some of your other IG products. Please
address the
       following:
           Please revise your future filings to provide a breakout of revenue
by product.
           Refer to Item 303(b)(2)(ii) of Regulation S-K and ASC 280-10-50-40.
           In light of the Voluntary Withdrawal in the first quarter of 2025,
please revise
           your future filings to disclose your methodology for how you account
for product
           returns and how the Voluntary Withdrawal had an impact on your
ability to make
 July 16, 2025
Page 2

           estimates of variable consideration vis a vis the gradual increase
in charges to the
           inventory valuation allowance over the last three years as shown in
your Schedule
           II.
             Consider providing a tabular rollforward of significant
adjustments to revenue
           such as product returns for the periods presented.

        In closing, we remind you that the company and its management are
responsible for
the accuracy and adequacy of their disclosures, notwithstanding any review,
comments,
action or absence of action by the staff.

       Please contact Jenn Do at 202-551-3743 or Kevin Vaughn at 202-551-3494
with any
questions.

                                                             Sincerely,

                                                             Division of
Corporation Finance
                                                             Office of Life
Sciences

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._